4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide and Brain Inflammation

4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide has been researched along with Brain Inflammation in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Begum M, ET; Sen, D	1

Other Studies

1 other study(ies) available for 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide and Brain Inflammation

Article	Year
DOR agonist (SNC-80) exhibits anti-parkinsonian effect via downregulating UPR/oxidative stress signals and inflammatory response in vivo. Neuroscience letters, 2018, 06-21, Volume: 678 Topics: Animals; Antiparkinson Agents; Benzamides; Disease Models, Animal; DNA Damage; Down-Regulation; Encephalitis; Male; Mice; Motor Activity; Oxidative Stress; Parkinson Disease; Piperazines; Receptors, Opioid, delta; Unfolded Protein Response	2018

Article

Year

DOR agonist (SNC-80) exhibits anti-parkinsonian effect via downregulating UPR/oxidative stress signals and inflammatory response in vivo.

Neuroscience letters, 2018, 06-21, Volume: 678

Topics: Animals; Antiparkinson Agents; Benzamides; Disease Models, Animal; DNA Damage; Down-Regulation; Encephalitis; Male; Mice; Motor Activity; Oxidative Stress; Parkinson Disease; Piperazines; Receptors, Opioid, delta; Unfolded Protein Response

2018